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The clinical heterogeneity of neuroblastoma
Neuroblastoma, a pediatric malignancy of the developing 
sympathetic  nervous  system,  is  a  multifaceted  disease 
with biological and clinical courses ranging from relent­
less progression to spontaneous regression or differentia­
tion into benign ganglioneuroma. Given these different 
phenotypes,  therapeutic  regimens  vary  between  wait­
and­see  approaches  to  the  most  intense  multimodal 
treatment.  Accurate  prediction  of  the  natural  clinical 
course of each individual patient at the time of diagnosis 
is  therefore  an  essential  prerequisite  for  therapeutic 
decision­making. Clinical variables such as stage of the 
disease and age of the patient at diagnosis are well estab­
lished predictors of neuroblastoma outcome. In addition, 
non­random cytogenetic aberrations have been shown to 
be associated with clinical courses in neuroblastoma and 
are  increasingly  used  in  risk  stratification  systems 
(reviewed  in  [1­3]).  Whereas  amplification  of  the 
oncogene MYCN and several other genomic alterations, 
such as loss of the chromosomal regions 1p and 11q or 
gain of 17q, have been shown to be strong markers of 
poor outcome, hyper­diploidy of the tumor cells is asso­
ciated with a favorable clinical phenotype [4]. However, 
whereas  current  risk  estimation  systems  for  neuro­
blastoma mostly succeed in discriminating patients with 
divergent outcomes, further improvements are required 
to prevent fatal events in low­risk and intermediate­risk 
groups and to avoid unnecessary cytotoxic treatment of 
patients in whom spontaneous regression will occur.
Clinical significance of complex chromosomal 
alterations in neuroblastoma
The  advent  of  microarray­based  comparative  genomic 
hybridization (array­CGH) has facilitated the analysis of 
chromosomal alterations in the cancer genome, provid­
ing  pangenomic  alteration  profiles  with  excep  tional 
spatial resolution in a single experiment [5]. Initial array­
CGH studies of primary neuroblastomas [6,7] confirmed 
the clinical significance of known copy number variations 
and narrowed down breakpoint regions of non­random 
chromosome aberrations. In a recent survey, Caren et al. 
[8] investigated 165 primary neuroblastomas using Affy­
metrix 250K single nucleotide polymorphism arrays and 
compared the survival of patient subgroups defined by 
genomic alterations. Patients with only numerical chromo­
somal aberrations and no other alteration had a favorable 
long­term outcome. In contrast, the survival of patients 
characterized by MYCN amplification, loss of 11q or gain 
of  17q  was  considerably  worse,  whereas  no  death  or 
disease was observed in patients with tumors harboring 
segmental  chromosome  alterations  other  than  those 
previously mentioned. These findings support results from 
previous  studies  indicating  that  a  limited  number  of 
predictive  genomic  alterations  are  sufficient  for  risk 
assessment of neuroblastoma patients (reviewed in [2]).
Results  from  another  recent  survey  by  Janoueix­
Lerosey et al. [9], however, indicated that global genomic 
profiles  may  add  significant  prognostic  information  to 
current neuroblastoma risk estimation. In this study [9], 
the prognostic significance of overall genomic alterations 
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blastomas by bacterial artificial chromosome array­CGH. 
Whereas patients with tumors showing only numerical 
chromosome aberrations had an excellent survival, those 
with  tumors  harboring  segmental  genomic  alterations 
showed  a  high  risk  of  relapse  and  a  poor  outcome. 
Amplification  of  MYCN  was  confirmed  to  be  a  strong 
predictor of adverse outcome, but other single genomic 
alterations,  such  as  loss  of  11q  or  gain  of  17q,  were 
overridden  by  the  presence  of  any  kind  of  segmental 
alterations in multivariate analyses.
Another  significant  difference  between  these  two 
studies [8,9] was noticed in the fraction of tumors with 
only numerical chromosome alterations. In the work of 
Janoueix­Lerosey et al. [9], this subgroup comprised 47% 
of the tumors, whereas it accounted for 28% of the cases 
in  the  study  of  Caren  et  al.  [8].  Similar  to  the  latter 
findings [8], this subgroup constituted 21% of the cases in 
a preliminary analysis of our array­CGH data [3]. These 
differences  might  in  part  be  attributed  to  distinct 
compositions  of  the  cohorts  under  investigation. 
However,  they  may  also  result  from  the  lower  spatial 
resolution  of  the  microarrays  used  in  the  study  of 
Janoueix­Lerosey et al. [9] than in the other surveys [3,8], 
which might have resulted in the detection of a smaller 
fraction of tumors with small gains or deletions and in 
the classification of fewer patients into subgroups with 
segmental  aberrations.  Taken  together,  although  the 
results  of  these  two  comprehensive  studies  [8,9]  are 
promising  with  respect  to  prognostic  classification  of 
neuroblastoma using array­CGH, the clinical significance 
of  global  genomic  alterations  needs  to  be  further 
evaluated  in  independent  studies  and  compared  with 
current risk estimation strategies.
An inherent disadvantage of array­CGH analysis is its 
propensity to disregard low­level copy number losses or 
gains in samples with a high proportion of contaminating 
stromal  cells.  This  potential  bias  has  been  taken  into 
account by Janoueix­Lerosey et al. [9] by analyzing only 
samples with a tumor content of at least 60%, whereas the 
tumor content was not specified in the study of Caren et 
al. [8]. This discrepancy in the experimental set­up may 
have resulted in a higher fraction of flat genomic profiles 
(that is, with no alterations) in the latter study (19%) [8] 
as  compared  with  the  former  study  (4%)  [9].  This 
suggestion  is  supported  by  the  finding  of  only  2%  flat 
genomic  profiles  in  another  study  in  which  a  tumor 
content of 60% had been used for sample selection [6]. 
Because of the rare occurrence of neuroblastomas with­
out any chromosomal alterations, the clinical outcome of 
these patients has so far remained elusive. Nevertheless, 
the routine application of array­CGH in clinical practice 
might be considerably limited by the issue of contami­
nating stromal cells, because defined thresholds of tumor 
content  will  a  priori  exclude  a  substantial  fraction  of 
samples from the analysis. In addition, genomic hetero­
geneity within a single tumor might be missed by array­
CGH analysis. Although the frequency and the clinical 
consequences  of  genomic  heterogeneity  in  neuro­
blastoma need to be clarified [10], it might be advisable 
to  complement  array­CGH  analyses  of  neuroblastoma 
samples  with  methods  for  detecting  chromosomal 
aberrations on the single cell level, such as fluorescence 
in situ hybridization, to evaluate the concordance of the 
results and to validate the clinical implications in large 
patient cohorts.
As an alternative to the overall genomic pattern as a 
prognostic marker, several reports have provided com­
pel  ling  evidence  that  specific  gene­expression  patterns 
can predict the natural courses of neuroblastoma patients 
with unprecedented accuracy [11­15]. These studies have 
shown that gene­expression­based classifiers can distin­
guish patients with contrasting clinical courses in almost 
all  prognostic  subgroups,  including  those  defined  by 
prognostic genomic makers such as MYCN amplification 
or loss of 11q [11,14]. A systematic comparison of global 
genomic and transcriptomic classification results is still 
lacking, however. The routine application of expression­
based prognostic markers in clinical practice might be 
limited by the instability of mRNA in comparison with 
DNA, which will require strict adherence to elaborated 
standard  operating  procedures  in  the  processing  of 
tumor  samples.  In  addition,  similar  to  array­CGH 
approaches,  classification  results  of  gene­expression­
based  predictors  might  be  influenced  by  the  relative 
amounts of stromal cells in the samples. In contrast to 
classifications based on genomic alterations, however, the 
prognostic significance of gene­expression profiles might 
be conferred by the stromal cells themselves, as has been 
described in other cancer entities, such as lymphoma or 
breast cancer [16,17]. Re­evaluation of the gene functions 
from existing gene­expression classifiers and validation 
of the predictive accuracy in neuroblastoma cohorts with 
low tumor contents will reveal the contribution of non­
tumorous  cells  to  the  prognostic  validity  of  gene­
expression­based classifiers in neuroblastoma.
Biological classification of neuroblastoma by 
chromosome alterations
Because of the strong association of numerical and seg­
mental cytogenetic alterations with patient outcome, it 
has  been  suggested  that  neuroblastoma  comprises  two 
distinct clinico­genetic classes [18]. The first type corres­
ponds  to  patients  with  favorable  outcome  and  is 
characterized  by  mitotic  dysfunction  leading  to  whole 
chromosome  gains  or  losses,  whereas  the  second  type 
corresponds to aggressive disease and is characterized by 
defects  in  maintaining  genomic  stability  leading  to 
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supported  by  the  study  of  Janoueix­Lerosey  et  al.  [9]. 
Given the prevalence of MYCN amplification and loss of 
11q  in  unfavorable  neuroblastoma,  and  the  inverse 
correlation  between  these  aberrations  in  high­risk 
neuroblastoma,  it  has  been  furthermore  hypothesized 
that the natural behavior of high­risk tumors is mainly 
conferred by these two aberrations [19,20]. In the work of 
Caren et al. [8], this suggestion was substantiated by the 
finding that patients with MYCN amplification and those 
with loss of 11q differed significantly in both their age at 
diagnosis  and  their  median  survival  time.  However, 
whereas the influence of MYCN amplification on aggres­
sive  growth  in  neuroblastoma  has  been  mostly  proven 
[1], the effect of 11q loss on neuroblastoma biology is less 
clear. In a recent integrative genomics analysis of primary 
neuroblastoma,  it  was  demonstrated  that  tumors  with 
loss  of  11q  make  up  two  distinct  biological  subgroups 
that differ in their clinical phenotype as well as in their 
gene­expression patterns [11]. These results suggest that 
11q loss is not a primary determinant of neuroblastoma 
tumor  behavior,  indicating  that  the  biology  of 
neuroblastoma is more complex than the association of 
genomic alterations with patient outcome might suggest. 
We  expect  that  the  emerging  application  of  next­
generation sequencing will unravel novel genomic altera­
tions that contribute to the programming of the various 
neuroblastoma phenotypes, which will lead to a refined 
molecular classification of this malignancy.
The future: will genomic profiles have prognostic 
value in the clinic?
The  prognostic  significance  of  specific  single  genomic 
markers is well established in neuroblastoma, and has led 
to  their  implementation  in  current  risk  assessment. 
Recent  studies  suggested  that  overall  genomic  profiles 
may  further  improve  neuroblastoma  risk  estimation. 
Before  routine  use  in  clinical  practice,  the  prognostic 
impact of global genomic alterations needs to be valid­
ated  prospectively  and  compared  with  current  stratifi­
cation  systems.  In  addition,  it  needs  to  be  evaluated 
whether  analysis  of  overall  genomic  profiles,  gene­
expression­based classifiers, or the combination of both 
will contribute most to an improved risk estimation of 
children with neuroblastoma. In any case, such analysis 
will require elaborate standard operating procedures to 
avoid  technical  pitfalls  and  defined  interpretation 
guidelines  to  ensure  reliable  treatment  stratification  of 
each individual patient in future clinical trials.
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